Seviteronel
CRPC
Innocrin PharmaceuticalSmall moleculePhase 2Dormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the CRPC cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bind-014 BIND Therapeutics | Phase 2 | B |
IMIFOPLATIN Promontory Therapeutics Inc. | Phase 2 | CCC |
pt-112 Promontory Therapeutics Inc. | Phase 2 | CCC |
Trastuzumab Deruxtecan Washington D.C. Veterans Affairs Medical Center | Phase 2 | CCC |
Jab-8263 Jacobio Pharmaceuticals Co., Ltd. | Phase 1/2 | CCC |
otx015 Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 | C |
Same molecule, other indications
Seviteronel is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →